Enhancing Domestic Drug Manufacturing Competitiveness Act

HR 1405 directs the Comptroller General (GAO) to study regulatory barriers hindering the expansion or siting of new pharmaceutical manufacturing facilities in the U.S. This study specifically examines how environmental and other regulations delay or increase costs for manufacturers compared to other countries, and assesses impacts on supply chain resiliency. The GAO must engage stakeholders to identify barriers, potential technological solutions, and needed policies, then submit a report to Congress within one year. The bill does not change regulations itself but aims to provide data and recommendations to improve U.S. competitiveness in drug manufacturing.